Theratechnologies (THTX) shares were up 50% in recent premarket activity Wednesday after the company said overnight that the US Food and Drug Administration approved its supplemental biologics license application for the new formulation of tesamorelin to be used as an injection.
The company said the tesamorelin injection is approved in the US for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy.
The company plans to commercialize the new F8 formulation under the tradename EGRIFTA WR.
EGRIFTA WR only needs weekly reconstitution and requires less than half the administration volume as the current F4 formulation -- sold in the US as EGRIFTA SV -- which is reconstituted daily, the company said.
The new formulation, which is patent-protected in the US through 2033, will replace EGRIFTA SV.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.